Here are the DEF 14A proxy statements from Perrigo Company plc (PRGO) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow PRGO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PRGO filings page.
Perrigo Company plc is asking shareholders to vote at its April 30, 2026 AGM in Dublin on nine director nominees, auditor ratification, say‑on‑pay, a new 2026 Long‑Term Incentive Plan, and renewed Irish share issuance and pre‑emption opt‑out authorities.
The proxy highlights 2025 progress under Perrigo’s “3‑S” plan, including reported net sales of $4.3 billion, adjusted operating income of $622 million with a 14.6% margin, and adjusted EPS of $2.75, up 7%. Cost programs delivered roughly $163 million and $157 million in gross annualized savings, while an agreed Dermacosmetics divestiture is valued at up to €327 million.
Executive pay remains heavily performance‑based, with about 87% of the CEO’s target compensation at risk and 2025 annual incentive payouts below target. The board emphasizes strong governance, majority‑independent membership, proxy access, ESG and cybersecurity oversight, and strict anti‑hedging and share ownership policies.